



Biotech Daily

Thursday March 15, 2018

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: DIMERIX UP 8%; UNIVERSAL BIO DOWN 6%**
- * **VICTORIA, DANA FARBER, BOSTON CHILDREN'S CANCER DEAL**
- * **TELIX, RADBOUD WORK ON TLX-250 FOR KIDNEY CANCER IMAGING**
- * **SIMAVITA SECURES \$1.4m IN CONVERTIBLE NOTES**
- * **OBJ: PROCTOR & GAMBLE PATENT, EXCLUSIVITY AGREEMENTS**
- * **ORTHOCELL WELCOMES FDA STEM CELL ACCELERATION**
- * **ALAN BEASLEY SPILLS HYDROPONICS; CEO DAVID RADFORD GOES**
- * **CRESO PARTNERS WITH FRIKE ON MARIJUANA FOR OSTEOARTHRITIS**
- * **VOLPARA MOVES 51m SHARES FROM ASX TO VOLUNTARY ESCROW**
- * **CATHERINE COSTELLO REPLACES ADMEDUS CO SEC TANYA MANGOLD**

MARKET REPORT

The Australian stock market fell 0.24 percent on Thursday March 15, 2018, with the ASX200 down 14.5 points to 5,920.8 points.

Thirteen of the Biotech Daily Top 40 stocks were up, 13 fell, 13 traded unchanged and one was untraded.

Dimerix was the best, up one cent or 7.7 percent to 14 cents with 5,443 shares traded.

Immutep improved four percent; Ellex was up three percent; Benitec, Impedimed, Mesoblast, Neuren and Reva rose more than two percent; Nanosonics, Orthocell and Uscom were up more than one percent; with Sirtex and Volpara up less than one percent.

Universal Biosensors led the falls, down 1.5 cents or 5.9 percent to 24 cents with 232,756 shares traded.

Opthea lost five percent; Admedus fell 4.8 percent; ITL was down three percent; Compumedics shed 2.9 percent; Bionomics, Cyclopharm, Medical Developments, Pharmaxis, Polynovo, Pro Medicus and Starpharma were down more than one percent; with Clinuvel, Cochlear, CSL and Resmed down by less than one percent.

VICTORIA GOVERNMENT

The Victoria Government says it has signed agreements with the Boston-based Dana Farber Cancer Institute and the Boston Children's Hospital.

A media release from the Minister for Health Jill Hennessy said that the agreement would build on an existing agreement between the Dana Farber Cancer Institute, a teaching affiliate of Harvard Medical School, and Victoria's Peter MacCallum Cancer Centre.

The media release said that the agreement would bring together medical researchers and healthcare professionals with colleagues in cancer and paediatric and health and "improve access to...medical breakthroughs" for Victorian patients.

The State Government said that "a number of concrete actions" were agreed between the Boston Children's Hospital and Melbourne's Royal Children's Hospital, including collaboration with the International Consortium for Health Outcomes Measurement on a core set of global standards for paediatrics to improve the safety and quality of care.

The Victoria Government said that an international working group of patients, parents and leading clinicians and academics would "establish key areas of research that matter most to families".

The media release said that Peter MacCallum Cancer Centre researcher Dr Elaine Sanij had won an award from the Cancer Centre for emerging female researchers and received \$10,000 to support her travel to the Dana Farber Cancer Institute.

The Government said that the agreements were finalized as part of a delegation to the US to "strengthen international ties between Victoria and some of the world's most prestigious health and medical research institutions".

Ms Hennessy said that while cancer survival rates in Victoria were among the best in the world, the "partnership with Dana Farber Cancer Institute will help save even more lives by working together on future medical breakthroughs".

TELIX PHARMACEUTICALS

Telix says it has a clinical collaboration with the Nijmegen, Netherlands-based Radboud University Medical Centre on TLX-250 for imaging clear cell renal cell cancer.

Telis said the collaboration on TLX-250, or 89Zr-girentuximab, would cover several clinical projects, including the pre-phase III bridging dosimetry study for TLX-250, participating as a key adviser for the phase III study, as well as the 'Impact-RCC' study to better understand how molecular imaging could be used to measure therapeutic treatment response in metastatic kidney cancer.

Telix co-founder and chief medical officer Dr Andreas Kluge said that Radboud had been a clinical leader in the use of 89Zr-Girentuximab in the clinic and its experience "underpins much of the confidence we have in the imaging agent, particularly the change in isotope to a radiometal for superior image quality, sensitivity and patient convenience".

Radboud Department of Urology chairman Prof Peter Mulders said his Centre was "pleased to be working with Telix to progress this very important technology".

"This international collaboration lays the foundation for the completion of product development of 89Zr-Girentuximab and we are delighted to be part of bringing this technology to renal cancer patients in the Netherlands and beyond," Prof Mulders said.

Telix said that as part of the collaboration it would fund a clinical fellowship at the Radboud's Department of Radiology and Nuclear Medicine to oversee activities around the collaboration.

The company said that the Radboud Technology Centre imaging facility which had technology and expertise for pre-clinical and clinical imaging would be a partner.

Telix was unchanged at 48 cents.

SIMAVITA

Simavita says it has commitments to raise \$1,400,000 through unsecured convertible notes subject to shareholder approval.

Simavita said the notes carried an interest rate of 10 percent a year and were convertible at four cents per Chess depository interest (CDI) and mature on March 31, 2019.

The company said that the funds would be used for working purposes, including the commercialization of its Alertplus technology platform for adult and infant incontinence.

The company said it intended to leave the convertible notes offer open with the possibility to raise a further \$100,000.

Simavita was untraded at two cents.

OBJ

OBJ says it has signed a patent and know-how licence agreement and amended an exclusivity agreement with Procter & Gamble.

OBJ said that the patent and know-how licence would cover the use of its electro-magnetic platform technology for commercial use in the skin care field.

The company said that execution of product licence term sheets, including royalties and subscription fees, would be negotiated in good faith.

In a separate ASX announcement, OBJ said that amendments to its product development agreement (PDA) with Procter & Gamble would release the Wave 1 Eye Wand device from exclusivity relating to "specific beauty sub-categories" of its magnetic array technology.

The company said that Procter & Gamble would allow its company to market its technology in other cosmetic applications, including colour cosmetics, haircare and shaving, specifically the cutting of hair rather than associated skincare, to other potential partners.

OBJ managing-director Jeffrey Edwards said that "OBJ's relationship with [Procter & Gamble] remains strong with the two companies continuing to explore new innovations and developments".

"At the same time, we also look forward to forming new partnerships with other companies, as this variation to the PDA allows us to make the existing technology available to others in the market," Mr Edwards said. "This will drive a wider awareness and increased adoption of the microarray technology."

OBJ was unchanged at 3.5 cents with 4.2 million shares traded.

ORTHOCELL

Orthocell says it welcomes the acceleration of approvals for regenerative medicine by the US Food and Drug Administration.

Orthocell said that following the FDA's regenerative medicine policy framework released in November, 2017, a recent article published in the New England Journal of Medicine by FDA commissioner Dr Scott Gottlieb and director of the FDA Centre for Biologics Evaluation and Research Dr Peter Marks reiterated the FDA's commitment to ensuring an efficient regulatory approval process for regenerative medicine products while maintaining measures that ensured a high level of safety and efficacy.

In the article, Dr Gottlieb and Dr Marks said that "working within the existing regulatory framework, the FDA will make use of all available regulatory pathways and will adopt the use of some new principles that we believe will make the appropriate pre-market evaluation of stem-cell-based therapies more efficient."

Orthocell was up half a cent or 1.7 percent to 30 cents.

THE HYDROPONICS COMPANY

Hydroponics director and former chairman says all resolutions at today's board spill extraordinary general meeting were passed with 68 percent in favor and 32 percent against.

Last night after the market closed, Hydroponics said that chief executive officer David Radford tendered his resignation and this morning the company requested a trading halt pending its board composition following today's extraordinary general meeting.

The meeting was called by former chairman Alan Beasley in January to remove directors Ian Mutton, Mary Verschuer, Peter Wallace and Hamish Macdonald and appoint Steven Xu, Lou Cattelan and John Radcliff (BD: Jan 21, 2018).

Late this afternoon, Hydroponics published the results of meeting with more than 47 million votes, or about 68.5 percent, supporting the spill resolutions and more than 21.6 million votes, or about 31.5 percent, opposing them

A withdrawn resolution to remove any director appointed after the notice of meeting was filed was passed by 70.52 percent to 27.73 percent with 1.75 percent of the votes at the proxy's discretion.

Mr Beasley told Biotech Daily that following the vote director Steven Xu had been appointed acting chairman.

Mr Beasley said that the reason for the board spill was a previous reluctance of the board to appoint Mr Xu as a director and issues relating to corporate governance that he outlined in a notice to the ASX published on the Hydroponics page on January 12, 2018.

Mr Radford was appointed as chief executive officer in October, starting on \$325,000 a year (BD: Oct 19, 2017).

Last night, Hydroponics said that Mr Radford had a three month notice period and would "manage a professional transition of current projects currently underway to the future management team" when suitable candidates were identified.

The company said that as a result of his resignation Mr Radford had withdrawn his candidacy for election at the annual general meeting planned for March 23, 2018 and would resign from all subsidiary boards.

The company was in a trading halt until March 19, 2018 and last traded at 60 cents.

CRESO PHARMA

Creso says it will partner with Mönchaltorf, Switzerland-based Frike Technologies for food additives and cosmetics to relieve osteoarthritis muscle and joint pain.

Creso says its Cannadol cannabidiol-based food supplement would be provided "across Europe" in two different strengths and would be registered as a cosmetic in the European Union.

The company said that Cannadol was intended to be used for the management of pain associated with sports injuries and age-related symptoms such as stiffness and arthritis.

Creso chief executive officer Dr Miri Halperin Wernli said that perceptions of cannabis consumption had changed.

"Cannabis is no longer something to get high on," Dr Halperin Wernli said.

"In the scientific community, [cannabidiol] advocacy is on the rise and evidence of its effectiveness across various health issues is growing," Dr Halperin Wernli said.

"As cannabis legalization spreads around the globe, a unique market based on the health appeals of [cannabidiol] is emerging," Dr Halperin Wernli said.

Creso fell 3.5 cents or 4.1 percent to 81 cents with 1.3 million shares traded.

[VOLPARA HEALTH TECHNOLOGIES](#)

Volpara says that 51,482,213 shares will be released from ASX escrow on April 27, 2018 but be held in voluntary escrow for a further 12 months.

Volpara said that the shares were held by the company's founders and directors.

The company's most recent Appendix 3B new issue announcement said that Volpara had 94,010,908 shares available for trading on the ASX and that with the release of the 51,482,213 shares from escrow in April 2019, it would have a total of 145,493,121 shares tradable on the ASX.

Volpara was up half a cent or 0.7 percent to 69 cents.

[ADMEDUS](#)

Admedus says that Tanya Mangold has resigned as company secretary and legal counsel, effective immediately.

In February, Admedus said it had appointed Ms Mangold as company secretary and legal counsel, replacing Maja McGuire (BD: Feb 27, 2018).

Today, the company said that chief financial officer Catherine Costello had been appointed as company secretary and would carry out both roles.

Admedus said Ms Costello was appointed chief financial officer in November 2017, replacing Mark Ziirsen who was appointed in 2016 (BD: Aug 26, 2016).

The company said that Ms Costello was a graduate of the Australian Institute of Company Directors and the Governance Institute of Australia and has previously held company secretary roles.

Admedus fell 1.5 cents or 4.8 percent to 30 cents with one million shares traded.